Press Releases Archives | Page 74 of 116

APEX Biologix Expands its Footprint Through Investment by Desert Highlands Regenerative

April 16, 2021 By Cade Hildreth, Founder & President Leave a Comment

Merger enables an increased focus on product innovation, more cutting-edge regenerative medicine research and strategic collaborations with other complementary technology companies.

Salt Lake City, UT (April 16, 2021) – Desert Highlands Regenerative (DHR), a private equity group, has acquired a majority ownership of APEX Biologix (APEX), the designers and manufacturers of the XCELL Platelet Rich Plasma (PRP) and other regenerative medicine products. APEX also appointed to its senior management team Jeff Frey as Chief Commercial Officer. Jeff’s orthopedic and regenerative medicine experience spans 25 years with companies such as Johnson & Johnson Orthopedics, Integra Lifesciences, and Ortho Solutions. [Read more…]

World first: TreeFrog Therapeutics announces the production of a single batch of 15 billion iPS cells in a 10L bioreactor with exponential amplification of 276-fold per week

April 15, 2021 By Cade Hildreth, Founder & President Leave a Comment

Biomimetic 3D cell culture technology unlocks the manufacturing bottleneck of stem-cell derived cell therapies through exponential hiPSC growth in large-scale bioreactors, with best-in-class cell quality.

Bordeaux, France – April 13^th, 2021. French cell therapy company TreeFrog Therapeutics announces unprecedented exponential growth of human induced pluripotent stem cells (hiPSC) in a 10L bioreactor[1]. Using proprietary C-Stem^TM technology, TreeFrog Therapeutics amplified 50 million hiPSC into a single batch of 15 billion cells in 6.5 days, and company reports exceptional cell quality. Data will be presented at the International Society for Stem Cell Research (ISSCR) Virtual Meeting, taking place June 21 – 26, 2021. [Read more…]

Organicell And Oklahoma State University Enter Into Agreement To Study Zofin™ In Respiratory Diseases Caused By Virus Infections Of Pandemic Potential

April 14, 2021 By Cade Hildreth, Founder & President Leave a Comment

Miami, FL (April 14, 2021) – Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced that it has entered into an agreement with Oklahoma State University to evaluate Zofin^TM for the treatment of respiratory diseases caused by virus infections of pandemic potential. This study site follows the Company’s earlier announcement of the agreement reached with the Centers for Disease Control and Prevention (“CDC”) to conduct research to determine the anti-inflammatory and anti-infective effectiveness of Zofin™ in experimental models of influenza infection. [Read more…]

NeoProgen, Inc. Receives First Granted Patent for Method to Treat Cardiac Conditions using Neonatal Heart-derived Medicinal Signaling Cells (nMSCs) and/or their Secretomes/Exosomes from US Patent Office

April 13, 2021 By Cade Hildreth, Founder & President Leave a Comment

April 12, 2021, Baltimore, Maryland – NeoProgen, Inc., a pre-clinical stage company developing an exosome-based product from human neonatal heart-derived Medicinal Signaling Cells (nMSCs) for tissue repair and regeneration for the treatment of heart failure (HF) and other inflammatory diseases, announced that it has received a patent from the United States Patent Office Patent No.: US 10.967,007 B2 “Cardiac Stem Cells for Cardiac Repair”. The innovation was developed by Dr. Sunjay Kaushal, a pediatric cardiac surgeon, while he was at the University of Maryland, Baltimore and NeoProgen is the exclusive licensee of the newly issued patent. [Read more…]

Vitro Biopharma Receives FDA Authorization to Conduct a Clinical Trial Using AlloRx Stem Cells® to Treat COVID-19

April 8, 2021 By Cade Hildreth, Founder & President 1 Comment

Golden, Colorado-April 6, 2021 — Vitro Biopharma, Inc. announced receipt of FDA authorization and clearance to enroll patients in its phase I-IIa, randomized, double-blinded, placebo controlled study of the safety and efficacy of therapeutic treatment with AlloRx Stem Cells® in adults with COVID-19. Our Investigational New Drug (IND) application will investigate the clinical effects of AlloRx Stem Cells® by studying safety and efficacy in patients with moderate to severe COVID-19. [Read more…]